Use of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole

dc.creatorSantamaría, Ana Lorena
dc.creatorDe Rissio, Ana María
dc.creatorRiarte, Adelina
dc.creatorGaravaglia, Patricia A
dc.creatorBruballa, Andrea Cecilia
dc.creatorRodriguez, Marcelo
dc.creatorIrazu, Lucía
dc.creatorRuiz, Andrés Mariano
dc.creatorGarcía, Gabriela Andrea
dc.date2020-12-22T17:30:47Z
dc.date2020-12-22T17:30:47Z
dc.date2013-06
dc.date.accessioned2023-08-29T20:08:11Z
dc.date.available2023-08-29T20:08:11Z
dc.identifier0732-8893
dc.identifierhttp://sgc.anlis.gob.ar/handle/123456789/1978
dc.identifier10.1016/j.diagmicrobio.2013.02.028
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8520034
dc.descriptionFil: Santamaría, Ana Lorena. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionFil: De Rissio, Ana María. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionFil: Riarte, Adelina. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionFil: Garavaglia, Patricia A. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionFil: Bruballa, Andrea Cecilia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionFil: Rodriguez, Marcelo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
dc.descriptionFil: Irazu, Lucía . ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
dc.descriptionFil: Ruiz, Andrés Mariano. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionFil: García, Gabriela Andrea. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
dc.descriptionTc13Tul antigen is expressed in the mammalian stages of Trypanosoma cruzi, the etiological agent of Chagas' disease. Here, we designed and validated an enzyme-linked immunosorbent assay using the recombinant Tc13Tul (Tc13Tul-ELISA) and found that it had 82.5% sensitivity and 97.05% of specificity. To evaluate whether the decrease in antibodies against Tc13Tul may be used as an early marker of the effect of chemotherapy with benznidazole, sera from 30 T. cruzi-infected children were evaluated by Tc13Tul-ELISA before and after benznidazole treatment. While in Group A (6 months-4 years old, n = 16) the decrease of more than 30% of Tc13Tul-ELISA values showed a sensitivity similar to that of conventional serology (CS); in Group B, (5-12 years old, n = 14) the decrease of Tc13Tul-ELISA values was a better parameter than negativization of CS to monitor the impact of treatment. Therefore, the dosage of anti-Tc13Tul antibodies may be useful as a methodology complementary to CS to evaluate chagasic patients undergoing chemotherapy with benznidazole.
dc.languageen
dc.publisherElsevier
dc.relationDiagnostic microbiology and infectious disease
dc.rightsnone
dc.sourceDiagnostic Microbiology and Infectious Disease 2013; 76(2):197-205.
dc.subjectTrypanosoma cruzi
dc.titleUse of an enzyme-linked immunosorbent assay that utilizes the Tc13Tul antigen of Trypanosoma cruzi to monitor patients after treatment with benznidazole
dc.typeArtículo


Este ítem pertenece a la siguiente institución